Clinical Trial

Study of BHV-1300 in Graves' Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Protocol Amendment History 3 changes
notable Trial sites expanded: 13 -> 17 locations 2026-05-14
notable Primary completion pushed: 2026-09 -> 2027-09 2026-05-14
minor Completion pushed: 2026-09 -> 2027-09 2026-05-14
Trial Details
NCT Number NCT06980649
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Graves Disease
Enrollment 15 participants
Start Date 2025-08-21
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-31